{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:21:50Z","timestamp":1767676910429},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Latent viruses such as cytomegalovirus (CMV), Epstein\u2013Barr virus (EBV) and adenovirus (ADV) often reactivate in immunocompromised patients, contributing to poor clinical outcomes. A rapid reconstitution of antiviral responses via adoptive transfer of virus-specific T cells (VSTs) can prevent or eradicate even refractory infections. Here, we evaluate this strategy and the associated methodological, manufacturing and clinical advances.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>From the early pioneering but cumbersome efforts to isolate CMV-specific T cell clones, new approaches and techniques have been developed to provide quicker, safer and broader-aimed ex-vivo antigen-specific cells. New manufacturing strategies, such as the use of G-Rex flasks or \u2018priming\u2019 with a library of overlapping viral peptides, allow for culturing greater numbers of cells that could be patient-specific or stored in cell banks for off-the-shelf applications. Rapid isolation of T cells using major histocompatibility complex tetramer or cytokine capture approaches, or genetic reprogramming of cells to target viral antigens can accelerate the generation of potent cellular products.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Advances in the ex-vivo generation of VSTs in academic medical centres and as off-the-shelf blood bank-based or commercially produced reagents are likely to result in broader accessibility and possible manufacturing cost reduction of these cell products, and will open new therapeutic prospects for vulnerable and critically ill immunocompromised patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/moh.0000000000000461","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T01:22:24Z","timestamp":1534987344000},"page":"486-493","source":"Crossref","is-referenced-by-count":11,"title":["Restoring antiviral immunity with adoptive transfer of ex-vivo generated T cells"],"prefix":"10.1097","volume":"25","author":[{"given":"Edoardo","family":"Migliori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Muranski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.bbmt.2010.11.008","article-title":"Viral infections in immunocompromised patients","volume":"17","author":"Englund","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bmt.2015.330","article-title":"Analysis of nonrelapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation","volume":"51","author":"Tanaka","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MOT.0000000000000549","article-title":"Pulmonary infectious complications after hematopoietic stem cell transplantation: a practical guide to clinicians","volume":"23","author":"Gea-Banacloche","year":"2018","journal-title":"Curr Opin Organ Transplant"},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.semnephrol.2016.05.018","article-title":"Respiratory viruses: influenza, RSV, and adenovirus in kidney transplantation","volume":"36","author":"Hawkinson","year":"2016","journal-title":"Semin Nephrol"},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijid.2017.07.011","article-title":"Respiratory viruses in transplant recipients: more than just a cold. Clinical syndromes and infection prevention principles","volume":"62","author":"Abbas","year":"2017","journal-title":"Int J Infect Dis"},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2141.2011.08988.x","article-title":"Management of multidrug-resistant viruses in the immunocompromised host: review","volume":"156","author":"Sellar","year":"2012","journal-title":"Br J Haematol"},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"key":"R10-20230928","doi-asserted-by":"crossref","DOI":"10.1016\/j.medmal.2018.03.006","article-title":"Maribavir, brincidofovir and letermovir: efficacy and safety of new antiviral drugs for treating cytomegalovirus infections","author":"Frange","year":"2018","journal-title":"Med Mal Infect"},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/1471-2334-13-330","article-title":"Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient","volume":"13","author":"Schubert","year":"2013","journal-title":"BMC Infect Dis"},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12879-017-2854-2","article-title":"Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients","volume":"17","author":"Robin","year":"2017","journal-title":"BMC Infect Dis"},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jcyt.2014.02.010","article-title":"The clinical and financial burden of preemptive management of cytomegalovirus disease after allogeneic stem cell transplantation: implications for preventive treatment approaches","volume":"16","author":"Jain","year":"2014","journal-title":"Cytotherapy"},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/blood-2010-06-289991","article-title":"Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects","volume":"116","author":"Melenhorst","year":"2010","journal-title":"Blood"},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/bmt.2016.17","article-title":"Virus-specific T-cell banks for \u2019off the shelf\u2019 adoptive therapy of refractory infections","volume":"51","author":"O\u2019Reilly","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R19-20230928","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"R20-20230928","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","article-title":"Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation","volume":"330","author":"Papadopoulos","year":"1994","journal-title":"N Engl J Med"},{"key":"R21-20230928","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"key":"R23-20230928","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2016-01-628982","article-title":"T cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood"},{"key":"R24-20230928","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat Med"},{"key":"R25-20230928","doi-asserted-by":"crossref","first-page":"14015","DOI":"10.1038\/mtm.2014.15","article-title":"Optimizing the production of suspension cells using the G-Rex \u2018M\u2019 series","volume":"1","author":"Bajgain","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R26-20230928","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"key":"R27-20230928","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/CJI.0b013e3181c0c3cb","article-title":"Accelerated production of antigen-specific T cells for preclinical and clinical applications using Gas-permeable rapid expansion Cultureware (G-Rex)","volume":"33","author":"Vera","year":"2010","journal-title":"J Immunother"},{"key":"R28-20230928","first-page":"278","article-title":"Adoptive T cell therapy for the treatment of viral infections","volume":"3","author":"Arasaratnam","year":"2015","journal-title":"Ann Transl Med"},{"key":"R29-20230928","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"key":"R30-20230928","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"R31-20230928","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"key":"R32-20230928","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv"},{"key":"R33-20230928","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3109\/14653249.2011.575356","article-title":"Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein\u2013Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation","volume":"13","author":"Hanley","year":"2011","journal-title":"Cytotherapy"},{"key":"R34-20230928","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.omtm.2017.02.001","article-title":"Toward a rapid production of multivirus-specific T cells targeting BKV, adenovirus, CMV, and EBV from umbilical cord blood","volume":"5","author":"Dave","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"R35-20230928","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa2546","article-title":"CMV-specific T cells generated from naive T cells recognize atypical epitopes and may be protective in vivo","volume":"7","author":"Hanley","year":"2015","journal-title":"Sci Transl Med"},{"key":"R36-20230928","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/blood-2009-03-213256","article-title":"Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes","volume":"114","author":"Hanley","year":"2009","journal-title":"Blood"},{"key":"R37-20230928","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jim.2007.01.001","article-title":"Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens","volume":"320","author":"Neudorfer","year":"2007","journal-title":"J Immunol Meth"},{"key":"R38-20230928","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jcyt.2014.05.023","article-title":"Clinical-scale isolation of \u2018minimally manipulated\u2019 cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease","volume":"16","author":"Odendahl","year":"2014","journal-title":"Cytotherapy"},{"key":"R39-20230928","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1537-2995.2010.02940.x","article-title":"Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation: streptamer-based adoptive T-cell transfer","volume":"51","author":"Schmitt","year":"2011","journal-title":"Transfusion"},{"key":"R40-20230928","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2013-12-547349","article-title":"Lowest numbers of primary CD8+ T cells can reconstitute protective immunity upon adoptive immunotherapy","volume":"124","author":"Stemberger","year":"2014","journal-title":"Blood"},{"key":"R41-20230928","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2006.06108.x","article-title":"Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation","volume":"134","author":"Feuchtinger","year":"2006","journal-title":"Br J Haematol"},{"key":"R42-20230928","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","article-title":"Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1\u2013specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation","volume":"31","author":"Icheva","year":"2013","journal-title":"J Clin Oncol"},{"key":"R43-20230928","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/ciq042","article-title":"Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation","volume":"52","author":"Peggs","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R44-20230928","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-017-0469-0","article-title":"Curative or preemptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I\/II multicenter clinical trial","volume":"10","author":"Qian","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R45-20230928","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"R46-20230928","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/leu.2017.39","article-title":"Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia","volume":"31","author":"Rossig","year":"2017","journal-title":"Leukemia"},{"key":"R47-20230928","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease","volume":"110","author":"Savoldo","year":"2007","journal-title":"Blood"},{"key":"R48-20230928","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/CJI.0b013e318177092b","article-title":"Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor","volume":"31","author":"Foster","year":"2008","journal-title":"J Immunother"},{"key":"R49-20230928","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J Clin Oncol"},{"key":"R50-20230928","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/bjc.2017.475","article-title":"A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy","volume":"118","author":"Cho","year":"2018","journal-title":"Br J Cancer"},{"key":"R51-20230928","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s10875-006-6532-1","article-title":"Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: a novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma","volume":"26","author":"Jurgens","year":"2006","journal-title":"J Clin Immunol"},{"key":"R52-20230928","doi-asserted-by":"crossref","first-page":"e22590","DOI":"10.4161\/onci.22590","article-title":"Human MHC class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo","volume":"2","author":"Xue","year":"2013","journal-title":"Oncoimmunology"},{"key":"R53-20230928","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.4049\/jimmunol.0902233","article-title":"CMV-specific TCR-transgenic T cells for immunotherapy","volume":"183","author":"Schub","year":"2009","journal-title":"J Immunol"},{"key":"R54-20230928","doi-asserted-by":"crossref","first-page":"10464","DOI":"10.1128\/JVI.05039-11","article-title":"Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope","volume":"85","author":"Oh","year":"2011","journal-title":"J Virol"},{"key":"R55-20230928","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.4161\/hv.24051","article-title":"Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy","volume":"9","author":"Berdien","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"R56-20230928","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1038\/srep04166","article-title":"Building and optimizing a virus-specific T cell receptor library for targeted immunotherapy in viral infections","volume":"4","author":"Banu","year":"2014","journal-title":"Sci Rep"},{"key":"R57-20230928","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1172\/JCI93024","article-title":"Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection","volume":"127","author":"Kah","year":"2017","journal-title":"J Clin Invest"},{"key":"R58-20230928","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J Hepatol"},{"key":"R59-20230928","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11904-018-0388-x","article-title":"Quarter CENTURY of anti-HIV CAR T cells","volume":"15","author":"Wagner","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"key":"R60-20230928","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jcyt.2016.04.007","article-title":"T-cell therapies for HIV: preclinical successes and current clinical strategies","volume":"18","author":"Patel","year":"2016","journal-title":"Cytotherapy"},{"key":"R61-20230928","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/mt.2015.70","article-title":"Engineering T cells to functionally cure HIV-1 infection","volume":"23","author":"Leibman","year":"2015","journal-title":"Mol Ther"},{"key":"R62-20230928","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V96.3.785.015k10_785_793","article-title":"Prolonged survival and tissue trafficking following adoptive transfer of CD4 (gene-modified autologous CD4? and CD8? T cells in human immunodeficiency virus\u2013infected subjects","volume":"96","author":"Mitsuyasu","year":"2000","journal-title":"Blood"},{"key":"R63-20230928","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol Ther"},{"key":"R64-20230928","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","article-title":"Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells","volume":"25","author":"Hale","year":"2017","journal-title":"Mol Ther"},{"key":"R65-20230928","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbmt.2017.10.004","article-title":"Virus-specific T cells: broadening applicability","volume":"24","author":"Barrett","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R66-20230928","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jcyt.2016.09.013","article-title":"Herpes simplex virus type 1 (HSV-1) specific T-cell generation from HLA-A1- and HLA-A2-positive donors for adoptive immunotherapy","volume":"19","author":"Ma","year":"2017","journal-title":"Cytotherapy"},{"key":"R67-20230928","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2015.07.005","article-title":"Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"17","author":"Ma","year":"2015","journal-title":"Cytotherapy"},{"key":"R68-20230928","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/cid\/cis844","article-title":"Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus","volume":"56","author":"Hirsch","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R69-20230928","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.bbmt.2013.05.005","article-title":"Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients","volume":"19","author":"Renaud","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"R70-20230928","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/infdis\/jix358","article-title":"Immunologic profiling of human metapneumovirus for the development of targeted immunotherapy","volume":"216","author":"Tzannou","year":"2017","journal-title":"J Infect Dis"},{"key":"R71-20230928","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jcyt.2016.08.010","article-title":"Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes","volume":"18","author":"McLaughlin","year":"2016","journal-title":"Cytotherapy"},{"key":"R72-20230928","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/4716","article-title":"In vivo migration and function of transferred HIV-1-specific cytotoxic T cells","volume":"5","author":"Brodie","year":"1999","journal-title":"Nat Med"},{"key":"R73-20230928","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood.V90.6.2196","article-title":"Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients","volume":"90","author":"Lieberman","year":"1997","journal-title":"Blood"},{"key":"R74-20230928","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/mt.2014.207","article-title":"Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy","volume":"23","author":"Lam","year":"2015","journal-title":"Mol Ther"},{"key":"R75-20230928","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.bbmt.2015.12.007","article-title":"Functionally active HIV-specific T cells that target Gag and Nef can be expanded from virus-naive donors and target a range of viral epitopes: implications for a cure strategy after allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Patel","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R76-20230928","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ebiom.2017.07.019","article-title":"Vorinostat renders the replication-competent latent reservoir of human immunodeficiency virus (HIV) vulnerable to clearance by CD8 T cells","volume":"23","author":"Sung","year":"2017","journal-title":"EBioMedicine"},{"key":"R77-20230928","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/infdis\/jiv022","article-title":"Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir","volume":"212","author":"Sung","year":"2015","journal-title":"J Infect Dis"},{"key":"R78-20230928","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.jcyt.2016.05.005","article-title":"Putting a price tag on novel autologous cellular therapies","volume":"18","author":"Abou-El-Enein","year":"2016","journal-title":"Cytotherapy"}],"container-title":["Current Opinion in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00062752-201811000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T02:28:05Z","timestamp":1695868085000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00062752-201811000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/moh.0000000000000461","relation":{},"ISSN":["1065-6251","1531-7048"],"issn-type":[{"value":"1065-6251","type":"print"},{"value":"1531-7048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}